Agios Pharmaceuticals Inc. (NASDAQ:AGIO) traded down 6.1% during mid-day trading on Wednesday . The stock traded as low as $38.11 and last traded at $38.49, with a volume of 800,387 shares traded. The stock had previously closed at $40.99.

Several equities research analysts recently issued reports on the stock. Canaccord Genuity restated a “hold” rating and issued a $50.00 target price on shares of Agios Pharmaceuticals in a report on Thursday, June 9th. Vetr cut shares of Agios Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $68.42 target price on the stock. in a report on Tuesday, June 7th. Zacks Investment Research cut shares of Agios Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, April 26th. SunTrust Banks Inc. raised their target price on shares of Agios Pharmaceuticals from $57.00 to $65.00 and gave the stock a “buy” rating in a report on Wednesday, May 18th. Finally, Credit Suisse Group AG raised their target price on shares of Agios Pharmaceuticals from $65.00 to $70.00 and gave the stock an “outperform” rating in a report on Wednesday, May 18th. Seven research analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. The company has an average rating of “Buy” and an average price target of $63.44.

The stock’s market cap is $1.47 billion. The company’s 50 day moving average is $42.14 and its 200 day moving average is $44.63.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($1.47) EPS for the quarter, missing the consensus estimate of ($0.48) by $0.99. During the same period in the previous year, the business posted ($0.85) EPS. The company had revenue of $6.98 million for the quarter, compared to analysts’ expectations of $39.62 million. The firm’s quarterly revenue was down 47.2% compared to the same quarter last year. Analysts anticipate that Agios Pharmaceuticals Inc. will post ($5.01) earnings per share for the current fiscal year.

In related news, Director Lewis Clayton Jr. Cantley sold 2,504 shares of the business’s stock in a transaction that occurred on Thursday, May 26th. The shares were sold at an average price of $51.69, for a total transaction of $129,431.76. Following the completion of the transaction, the director now owns 127,175 shares in the company, valued at approximately $6,573,675.75. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Scott Biller sold 27,500 shares of the business’s stock in a transaction that occurred on Wednesday, June 8th. The stock was sold at an average price of $65.00, for a total transaction of $1,787,500.00. Following the transaction, the insider now owns 81,376 shares of the company’s stock, valued at approximately $5,289,440. The disclosure for this sale can be found here.

An institutional investor recently raised its position in Agios Pharmaceuticals stock. Mutual of America Capital Management LLC boosted its stake in Agios Pharmaceuticals Inc. (NASDAQ:AGIO) by 0.5% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 17,325 shares of the biopharmaceutical company’s stock after buying an additional 86 shares during the period. Mutual of America Capital Management LLC’s holdings in Agios Pharmaceuticals were worth $1,125,000 as of its most recent filing with the SEC.

Agios Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery and development of orally available small molecule medicines for the treatment of cancer and rare genetic disorders (RGDs), which are a subset of orphan genetic metabolic diseases. Its cancer product candidates are AG-221 and AG-120, which targets mutated isocitrate dehydrogenase 2 and 1, or IDH2 and IDH1, respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.